ArticleHereditas2025
Structural and functional assessment of TBX20 gene variants in pediatric ventricular septal defect.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to investigate the potential role of TBX20 gene variants in the molecular pathogenesis of congenital ventricular septal defect (VSD) in pediatric patients.
methodsGenetic sequencing and variant detection were performed for the TBX20 gene, a T-box transcription factor, in a cohort of 150 pediatric patients diagnosed with VSD, recruited from the Department of Cardiothoracic Surgery at Shanxi Children's Hospital. Functional characterization of newly identified variants was conducted using homology-based protein structural modeling, dual-luciferase reporter assays, and quantitative real-time polymerase chain reaction (qRT-PCR).
resultsTwo variants within the highly conserved T-box DNA-binding domain were identified in five children: a synonymous variant c.576C > T (p.Thr192Thr) and a missense variant c.577G > A (p.Gly193Ser). Structural modeling predicted that the p.Gly193Ser substitution destabilized the TBX20 protein by altering its conformation and increasing its potential energy state. Functional assays demonstrated that this variant reduced TBX20 mRNA expression and significantly attenuated transactivation of the downstream target gene ANF. Bioinformatic analysis supported the deleterious functional impact of the p.Gly193Ser variant and its potential contribution to VSD pathogenesis. In contrast, the synonymous p.Thr192Thr variant was associated with increased transcriptional activity of TBX20 and enhanced regulation of ANF. qRT-PCR data indicated significantly reduced TBX20-G193S mRNA levels compared to wild-type (WT) when expressed independently (p < 0.01), but elevated levels in the presence of GATA4 and NKX2-5 (p < 0.001). Despite this, ANF transactivation remained significantly lower than WT, suggesting impaired functional capacity. These alterations may influence translational efficiency and contribute to abnormal cardiac septation.
conclusionThe findings underscore the involvement of TBX20 gene variants in the etiology of pediatric VSD and provide mechanistic insights that may inform future clinical research and the development of targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.